Pendulum Therapeutics launches first probiotic classified as a medical food to manage diabetes

Image courtesy of Pendulum Therapeutics

Pendulum Therapeutics (San Francisco, CA), has launched what the firm says is the first and only medical probiotic clinically shown to lower A1C and blood sugar spikes, called Pendulum Glucose Control. The product, classified as a medical food, is specifically designed to manage type 2 diabetes. Pendulum Glucose Control can be taken on top of metformin, a first line therapy for type 2 diabetes, under physician supervision as part of a total diabetes management plan.

"We're taking a new approach to managing type 2 diabetes through the gut microbiome with Pendulum Glucose Control," said Colleen Cutcliffe, PhD, CEO and co-founder of Pendulum Therapeutics, in a press release. "Medical probiotics are a new category of probiotics that deliver clinical efficacy for the management of a specific disease or condition with targeted and novel probiotic strains. Our patented formulation contains a novel and unique blend of a prebiotic and strains of beneficial probiotic bacteria that can't be found in any other probiotic on the market. And unlike 'off-the-shelf' probiotics with general 'gut health' claims, our medical probiotic has been clinically tested and shown to deliver meaningful benefits for managing blood sugar levels."

Identified using DNA sequencing, the novel, targeted probiotic strains help metabolize fiber and produce butyrate, a short-chain fatty acid that plays a key role in the body’s ability to signal insulin production and stabilize blood glucose. The novel strains also strengthen the gut lining to help support inflammation and utilize fiber to energize the colon. Pendulum Glucose Control is Non-GMO Project Verified, vegan, and gluten-free. It is sold directly to consumers, and does not require a doctor’s prescription, but physician supervision is highly recommended.